Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research at AdventHealth Central Florida, Professor of Medicine at the University of Central Florida, and at Loma Linda University Health, shared a post on LinkedIn:
“Precision oncology for urologic cancers – Bladder cancer, Prostate cancer, Kidney cancer.
Take home messages:
1) Precision medicine has emerged for some specific settings (UC: Erdafitinib for FGFR3 mutations/fusions, T-Dxd for HER2 IHC 3+, MRD ctDNA to select for adjuvant therapy; Prostate: PARPi for HRR/BRCA1-2, Lu-PSMA for PSMA-PET+, Pembro for MSI,TMB-high);
2) The roles for other biomarkers are emerging (UC: DV+PD1i for HER2 IHC 1+, RCC: KIM-1 for adjuvant therapy, Prostate: PTEN-/PI3K-AKT-mTOR alterations for AKTi or docetaxel, Decipher score for docetaxel in mCSPC, Decipher/MMAI for ADT with XRT for intermediate risk localized disease);
3) clinicaltrial participation should be preferred to expedite advances in developing new therapies and incorporating precision oncology;
4) Optimal collaboration between all stakeholders is necessary to make advances in precision oncology (investigators, industry, biotech, patient advocacy groups).
Thanks to Abhishek Mohanty for the invitation – Pleased to give this lecture at the BioBank India Foundation Interonc 26 conference at Maulana Azad Medical College, New Delhi, India from Adventhealth Cancer Institute.”
More posts featuring Guru Sonpavde
